Journals / Turkish Journal of Gastroenterology / 2020 / Cilt: 31 - Sayı: 8

Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn’s disease

Pages
566–572
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, it can be used in clinical research and practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Inflammatory bowel diseases (IBD) impair patients’ quality of life (QoL).
📊
Key Findings & Data:Materials and Methods: Patients filled self-report questionnaires (Turkish IBDQ [TrIBDQ] and 36-Item Short Form Health Survey [SF 36]) themselves under a physician’s supervision, and they were free to ask questions about the questionnaires.
💡
Conclusion & Impact:Thus, it can be used in clinical research and practice.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Inflammatory bowel diseases (IBD) impair patients’ quality of life (QoL). The IBD Questionnaire (IBDQ) is created to mea sure the health related QoL specific for IBD. We planned to investigate the validation and reliability of the Turkish translation of IBDQ. Materials and Methods: Patients filled self-report questionnaires (Turkish IBDQ [TrIBDQ] and 36-Item Short Form Health Survey [SF 36]) themselves under a physician’s supervision, and they were free to ask questions about the questionnaires. The participants then filled the same questionnaires after at least two weeks. Construct validity, discriminant ability, reliability, and susceptibility to change were analyzed separately for the patients with IBD. Intra-class correlation coefficient was used to assess test–retest reliability. Cron bach’s alpha values were used to assess internal consistency. Results: A 100 patients enrolled in the study, 53 with Crohn’s disease (CD) and 47 with ulcerative colitis (UC). We found a moder ate-to-high positive correlation between the TrIBDQ domains and the SF-36 dimensions. In UC and CD, TrIBDQ was able to differentiate active disease and remission. We found that Cronbach’s alpha for TrIBDQ domains ranged from 0.76 to 0.94 in CD and 0.79 to 0.92 in UC. The total Cronbach’s alpha for TrIBDQ was 0.96 in CD and 0.95 in UC. Sensitivity-to-change analyses of the bowel, systemic, and emotional scores showed statistically significant differences between their baseline and follow-up values. Conclusion: TrIBDQ is a valid and reliable tool for assessing the QoL in Turkish speaking patients who have IBD. Thus, it can be used in clinical research and practice.

🔖

Cite This Article

KANİ, H. T., ERGENÇ, İ., ARIKAN, H., KOMESLİ, Z., SEYREK, B., DEMİRTAŞ, C. Ö., ALAHDAB, Y. Ö., İMERYÜZ, N., ATUĞ, Ö. (2020). Validation and reliability of the Turkish version of the inflammatory bowel disease questionnaire for ulcerative colitis and Crohn’s disease. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 8, 566–572. https://ajindex.com/articles/408698

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Atug O, Kani HT, Banzragch M, Imeryuz N, Akin H. Incidence rate of anemia in inflammatory bowel diseases. Turk J Gastroenterol 2016; 27: 143-8. [Crossref] 2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42; quiz e30. [Crossref] 3. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006; 4: 1491-501. [Crossref] 4. Fiorino G, Allocca M, Chaparro M, et al. ‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohn’s Colitis 2018: 13: 127-37. [Crossref] 5. Leong RW, Lee YT, Ching JY, Sung JJ. Quality of life in Chinese patients with inflammatory bowel disease: validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire. Aliment Pharmacol Ther 2003; 17: 711-8. [Crossref] 6. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10. [Crossref] 7. Acquadro C, Conway K, Christelle G, I M. Linguistic Validation Manual for Patient-Reported Outcomes (PRO) Instruments. 2004. 8. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83. [Crossref] 9. Koçyiğit H, Aydemir Ö, Fişek G, Ölmez N, Memiş A. [Validity and reliability of Turkish version of short form 36 (SF-36)]. Ilaç ve tedavi dergisi 1999; 12: 102-6. 10. van Hees PA, van Elteren PH, van Lier HJ, van Tongeren JH. An index of inflammatory activity in patients with Crohn’s disease. Gut 1980; 21: 279-86. [Crossref] 11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9. [Crossref] 12. Lopez-Vivancos J, Casellas F, Badia X, Vilaseca J, Malagelada JR. Validation of the spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn’s disease. Digestion 1999; 60: 274-80. [Crossref] 13. Ren WH, Lai M, Chen Y, Irvine EJ, Zhou YX. Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 2007; 13: 903-10. [Crossref] 14. Irvine EJ, Feagan BG, Wong CJ. Does